| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 25 | 2009 | 244 | 2.080 |
Why?
|
| Antihypertensive Agents | 15 | 2009 | 81 | 1.870 |
Why?
|
| Echocardiography | 27 | 2015 | 113 | 1.380 |
Why?
|
| Hypertrophy, Left Ventricular | 17 | 2015 | 25 | 1.300 |
Why?
|
| Coronary Disease | 12 | 2004 | 66 | 1.240 |
Why?
|
| Cardiovascular Diseases | 11 | 2016 | 373 | 1.160 |
Why?
|
| Myocardial Infarction | 9 | 2004 | 147 | 0.900 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2009 | 25 | 0.660 |
Why?
|
| Ventricular Dysfunction, Left | 8 | 2011 | 46 | 0.620 |
Why?
|
| Electrocardiography | 12 | 2014 | 119 | 0.530 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2008 | 61 | 0.530 |
Why?
|
| Humans | 76 | 2016 | 28554 | 0.500 |
Why?
|
| Heart | 3 | 2015 | 68 | 0.500 |
Why?
|
| Calcium Channel Blockers | 2 | 2006 | 33 | 0.490 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2015 | 13 | 0.490 |
Why?
|
| Regeneration | 1 | 2015 | 21 | 0.490 |
Why?
|
| Neovascularization, Physiologic | 1 | 2015 | 24 | 0.490 |
Why?
|
| Cardiomyopathies | 1 | 2015 | 32 | 0.480 |
Why?
|
| Stem Cell Transplantation | 1 | 2015 | 43 | 0.480 |
Why?
|
| Stroke | 3 | 2010 | 276 | 0.450 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2003 | 29 | 0.430 |
Why?
|
| Risk Factors | 17 | 2015 | 2414 | 0.420 |
Why?
|
| Heart Failure | 6 | 2004 | 179 | 0.410 |
Why?
|
| Hypolipidemic Agents | 2 | 2003 | 28 | 0.410 |
Why?
|
| Heart Ventricles | 13 | 2004 | 115 | 0.360 |
Why?
|
| Ventricular Function, Left | 7 | 2009 | 45 | 0.360 |
Why?
|
| Acute Coronary Syndrome | 3 | 2014 | 16 | 0.350 |
Why?
|
| Heart Defects, Congenital | 1 | 2010 | 35 | 0.320 |
Why?
|
| Ramipril | 1 | 2009 | 1 | 0.320 |
Why?
|
| Benzoates | 1 | 2009 | 6 | 0.320 |
Why?
|
| Benzimidazoles | 1 | 2009 | 9 | 0.320 |
Why?
|
| Cardiology | 3 | 2014 | 57 | 0.320 |
Why?
|
| Angina, Unstable | 4 | 2014 | 12 | 0.310 |
Why?
|
| Diastole | 4 | 2009 | 32 | 0.310 |
Why?
|
| United States | 11 | 2015 | 2191 | 0.300 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2008 | 329 | 0.290 |
Why?
|
| Atrial Fibrillation | 2 | 2003 | 136 | 0.290 |
Why?
|
| Arteriosclerosis | 2 | 2005 | 13 | 0.270 |
Why?
|
| Oxazoles | 1 | 2006 | 2 | 0.260 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2006 | 3 | 0.260 |
Why?
|
| Drug Approval | 1 | 2006 | 7 | 0.260 |
Why?
|
| United States Food and Drug Administration | 1 | 2006 | 22 | 0.260 |
Why?
|
| Glycine | 1 | 2006 | 12 | 0.260 |
Why?
|
| Arrhythmias, Cardiac | 4 | 2003 | 73 | 0.250 |
Why?
|
| Coronary Angiography | 9 | 2004 | 84 | 0.250 |
Why?
|
| Blood Pressure | 7 | 2015 | 207 | 0.250 |
Why?
|
| Middle Aged | 34 | 2016 | 9322 | 0.240 |
Why?
|
| American Heart Association | 2 | 2014 | 18 | 0.240 |
Why?
|
| Coronary Artery Bypass | 3 | 2014 | 30 | 0.230 |
Why?
|
| Dobutamine | 2 | 1994 | 4 | 0.230 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2015 | 191 | 0.230 |
Why?
|
| Captopril | 1 | 2004 | 1 | 0.230 |
Why?
|
| Perindopril | 1 | 2004 | 1 | 0.230 |
Why?
|
| Tetrazoles | 1 | 2004 | 2 | 0.230 |
Why?
|
| Valine | 1 | 2004 | 6 | 0.220 |
Why?
|
| Double-Blind Method | 10 | 2004 | 433 | 0.220 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2004 | 9 | 0.220 |
Why?
|
| Echocardiography, Doppler | 6 | 2009 | 27 | 0.220 |
Why?
|
| Vitamins | 1 | 2004 | 21 | 0.220 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 3 | 2009 | 3 | 0.220 |
Why?
|
| Indoles | 1 | 2004 | 38 | 0.220 |
Why?
|
| Verapamil | 1 | 2004 | 26 | 0.220 |
Why?
|
| Cardiomegaly | 5 | 1993 | 9 | 0.220 |
Why?
|
| Exercise Test | 2 | 1994 | 122 | 0.210 |
Why?
|
| Metoprolol | 2 | 2003 | 8 | 0.210 |
Why?
|
| Losartan | 1 | 2003 | 2 | 0.210 |
Why?
|
| Pravastatin | 1 | 2003 | 10 | 0.210 |
Why?
|
| Heptanoic Acids | 1 | 2003 | 5 | 0.210 |
Why?
|
| Carbazoles | 1 | 2003 | 6 | 0.210 |
Why?
|
| Propanolamines | 1 | 2003 | 8 | 0.210 |
Why?
|
| Male | 36 | 2015 | 15401 | 0.210 |
Why?
|
| Carotid Artery Diseases | 1 | 2003 | 16 | 0.210 |
Why?
|
| Pyrroles | 1 | 2003 | 24 | 0.210 |
Why?
|
| Prevalence | 6 | 2010 | 467 | 0.210 |
Why?
|
| Female | 35 | 2015 | 15821 | 0.210 |
Why?
|
| Dietary Supplements | 1 | 2003 | 67 | 0.200 |
Why?
|
| Antioxidants | 1 | 2003 | 64 | 0.200 |
Why?
|
| Stroke Volume | 3 | 2001 | 58 | 0.200 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2002 | 39 | 0.200 |
Why?
|
| Prognosis | 7 | 2015 | 827 | 0.190 |
Why?
|
| Body Mass Index | 5 | 2015 | 467 | 0.190 |
Why?
|
| Life Style | 3 | 1999 | 201 | 0.190 |
Why?
|
| Incidence | 5 | 2015 | 774 | 0.180 |
Why?
|
| Aged | 26 | 2015 | 9344 | 0.180 |
Why?
|
| Follow-Up Studies | 7 | 2015 | 1863 | 0.170 |
Why?
|
| Risk Assessment | 6 | 2016 | 676 | 0.170 |
Why?
|
| Critical Care | 2 | 2002 | 199 | 0.170 |
Why?
|
| Treatment Outcome | 6 | 2009 | 3622 | 0.170 |
Why?
|
| Mitral Valve Prolapse | 3 | 1992 | 4 | 0.170 |
Why?
|
| Metabolic Syndrome | 2 | 2015 | 62 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 376 | 0.170 |
Why?
|
| Primary Prevention | 1 | 1999 | 35 | 0.160 |
Why?
|
| Blood Glucose | 3 | 2011 | 108 | 0.160 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 1997 | 10 | 0.150 |
Why?
|
| Ultrasonography | 7 | 2006 | 244 | 0.150 |
Why?
|
| Diabetes Mellitus | 4 | 2009 | 137 | 0.150 |
Why?
|
| Diabetic Angiopathies | 2 | 2015 | 6 | 0.140 |
Why?
|
| Drug Therapy, Combination | 2 | 2009 | 184 | 0.140 |
Why?
|
| Cardiac Catheterization | 2 | 2001 | 72 | 0.140 |
Why?
|
| Multicenter Studies as Topic | 3 | 2004 | 51 | 0.140 |
Why?
|
| Coronary Artery Disease | 2 | 2004 | 141 | 0.140 |
Why?
|
| Electric Countershock | 1 | 1996 | 11 | 0.140 |
Why?
|
| Heart Atria | 1 | 1996 | 30 | 0.130 |
Why?
|
| Hemodynamics | 4 | 2001 | 71 | 0.120 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2014 | 26 | 0.110 |
Why?
|
| Disease Management | 1 | 2014 | 115 | 0.110 |
Why?
|
| Reproducibility of Results | 6 | 2016 | 732 | 0.110 |
Why?
|
| Sensitivity and Specificity | 6 | 2004 | 520 | 0.110 |
Why?
|
| Quality of Life | 2 | 2001 | 659 | 0.110 |
Why?
|
| Heart Conduction System | 2 | 2003 | 12 | 0.100 |
Why?
|
| Heart Injuries | 1 | 1992 | 3 | 0.100 |
Why?
|
| Shock | 1 | 1992 | 11 | 0.100 |
Why?
|
| Heart Valve Diseases | 1 | 1992 | 18 | 0.100 |
Why?
|
| Myocardium | 1 | 1993 | 105 | 0.100 |
Why?
|
| Heart Diseases | 2 | 1992 | 70 | 0.100 |
Why?
|
| Animals | 3 | 2006 | 3814 | 0.090 |
Why?
|
| Insulin Resistance | 1 | 2011 | 52 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2015 | 1811 | 0.090 |
Why?
|
| Adult | 11 | 2016 | 8173 | 0.090 |
Why?
|
| Indians, North American | 1 | 2010 | 7 | 0.090 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2003 | 33 | 0.080 |
Why?
|
| Clinical Trials as Topic | 3 | 1999 | 239 | 0.080 |
Why?
|
| Sex Factors | 4 | 2006 | 477 | 0.080 |
Why?
|
| Contrast Media | 2 | 2004 | 75 | 0.080 |
Why?
|
| Exercise | 3 | 1999 | 472 | 0.080 |
Why?
|
| Global Health | 1 | 2009 | 42 | 0.080 |
Why?
|
| Heart Auscultation | 1 | 1988 | 1 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2009 | 46 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2003 | 70 | 0.080 |
Why?
|
| Mitral Valve | 1 | 1988 | 10 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 352 | 0.070 |
Why?
|
| Systole | 4 | 2009 | 18 | 0.070 |
Why?
|
| Tunica Intima | 2 | 2004 | 13 | 0.070 |
Why?
|
| Intensive Care Units | 3 | 1994 | 299 | 0.070 |
Why?
|
| Socioeconomic Factors | 3 | 2004 | 309 | 0.070 |
Why?
|
| Comorbidity | 4 | 2014 | 500 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2001 | 373 | 0.070 |
Why?
|
| Atherosclerosis | 1 | 2006 | 56 | 0.060 |
Why?
|
| Weight Loss | 2 | 1997 | 130 | 0.060 |
Why?
|
| Body Height | 1 | 2005 | 37 | 0.060 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2004 | 4 | 0.060 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2004 | 19 | 0.060 |
Why?
|
| Atenolol | 2 | 2003 | 2 | 0.060 |
Why?
|
| Carotid Stenosis | 1 | 2004 | 6 | 0.060 |
Why?
|
| Tunica Media | 1 | 2004 | 6 | 0.060 |
Why?
|
| Carotid Artery, Common | 1 | 2004 | 4 | 0.060 |
Why?
|
| Fluorocarbons | 1 | 2004 | 12 | 0.060 |
Why?
|
| Valsartan | 1 | 2004 | 1 | 0.060 |
Why?
|
| Albumins | 1 | 2004 | 19 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2006 | 359 | 0.060 |
Why?
|
| Homocysteine | 1 | 2004 | 8 | 0.060 |
Why?
|
| Forecasting | 2 | 2016 | 103 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 623 | 0.060 |
Why?
|
| Cohort Studies | 5 | 2011 | 1942 | 0.050 |
Why?
|
| Cerebrovascular Disorders | 1 | 2005 | 133 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2003 | 32 | 0.050 |
Why?
|
| Heart Function Tests | 2 | 2000 | 3 | 0.050 |
Why?
|
| Physician's Role | 1 | 2002 | 19 | 0.050 |
Why?
|
| Felodipine | 1 | 2001 | 1 | 0.050 |
Why?
|
| Age Factors | 2 | 2000 | 789 | 0.050 |
Why?
|
| Mississippi | 2 | 2016 | 3 | 0.050 |
Why?
|
| Manometry | 1 | 2001 | 17 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 1992 | 190 | 0.050 |
Why?
|
| Thrombolytic Therapy | 2 | 2002 | 51 | 0.050 |
Why?
|
| Myocardial Revascularization | 2 | 2000 | 20 | 0.040 |
Why?
|
| Critical Illness | 1 | 2002 | 135 | 0.040 |
Why?
|
| Ventricular Pressure | 1 | 2000 | 3 | 0.040 |
Why?
|
| Smoking | 2 | 2004 | 175 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2001 | 496 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 1999 | 19 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2000 | 61 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 1197 | 0.040 |
Why?
|
| Body Weight | 1 | 2000 | 145 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2004 | 270 | 0.040 |
Why?
|
| Clinical Enzyme Tests | 1 | 1997 | 2 | 0.040 |
Why?
|
| Collateral Circulation | 1 | 1997 | 6 | 0.040 |
Why?
|
| Sodium, Dietary | 1 | 1997 | 7 | 0.030 |
Why?
|
| Vascular Patency | 1 | 1997 | 18 | 0.030 |
Why?
|
| Algorithms | 2 | 2002 | 380 | 0.030 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 1997 | 5 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 1997 | 22 | 0.030 |
Why?
|
| Isoenzymes | 1 | 1997 | 53 | 0.030 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 1997 | 41 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 1997 | 79 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 1997 | 80 | 0.030 |
Why?
|
| Thrombosis | 1 | 1997 | 58 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 1997 | 148 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2016 | 84 | 0.030 |
Why?
|
| Recurrence | 1 | 1996 | 322 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 16 | 0.030 |
Why?
|
| Albuminuria | 1 | 2015 | 14 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2014 | 54 | 0.030 |
Why?
|
| Safety | 1 | 1994 | 45 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 1997 | 1213 | 0.030 |
Why?
|
| Organ Size | 2 | 2004 | 106 | 0.030 |
Why?
|
| Natriuresis | 1 | 1993 | 1 | 0.030 |
Why?
|
| Wakefulness | 1 | 1993 | 98 | 0.030 |
Why?
|
| Cats | 1 | 1992 | 30 | 0.020 |
Why?
|
| Arteries | 1 | 1992 | 16 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 1992 | 33 | 0.020 |
Why?
|
| Physicians' Offices | 1 | 1992 | 7 | 0.020 |
Why?
|
| Blood Pressure Determination | 1 | 1992 | 16 | 0.020 |
Why?
|
| Hypotension | 1 | 1992 | 29 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 722 | 0.020 |
Why?
|
| Heart Neoplasms | 1 | 1992 | 13 | 0.020 |
Why?
|
| Emergencies | 1 | 1992 | 36 | 0.020 |
Why?
|
| Dogs | 1 | 1992 | 193 | 0.020 |
Why?
|
| Rabbits | 1 | 1992 | 194 | 0.020 |
Why?
|
| Blood Flow Velocity | 2 | 1989 | 20 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 1992 | 74 | 0.020 |
Why?
|
| Fasting | 1 | 2011 | 22 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 1993 | 298 | 0.020 |
Why?
|
| Obesity | 2 | 2005 | 322 | 0.020 |
Why?
|
| Cardiac Output | 1 | 1989 | 14 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2004 | 934 | 0.020 |
Why?
|
| Biomarkers | 2 | 2004 | 601 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2004 | 990 | 0.020 |
Why?
|
| Tricuspid Valve | 1 | 1988 | 2 | 0.020 |
Why?
|
| Mitral Valve Insufficiency | 1 | 1988 | 4 | 0.020 |
Why?
|
| Tricuspid Valve Prolapse | 1 | 1988 | 2 | 0.020 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 1988 | 5 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2009 | 333 | 0.020 |
Why?
|
| Coronary Vessel Anomalies | 1 | 1988 | 4 | 0.020 |
Why?
|
| Intracranial Embolism and Thrombosis | 1 | 1986 | 2 | 0.020 |
Why?
|
| Auscultation | 1 | 1986 | 5 | 0.020 |
Why?
|
| Rupture, Spontaneous | 1 | 1986 | 5 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 1986 | 14 | 0.020 |
Why?
|
| Endocarditis, Bacterial | 1 | 1986 | 12 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2004 | 1397 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 4901 | 0.020 |
Why?
|
| Normal Distribution | 1 | 2004 | 5 | 0.010 |
Why?
|
| Raloxifene Hydrochloride | 1 | 2004 | 2 | 0.010 |
Why?
|
| Lipoproteins, HDL | 1 | 2004 | 24 | 0.010 |
Why?
|
| Cerebellum | 1 | 2005 | 47 | 0.010 |
Why?
|
| Postmenopause | 1 | 2004 | 55 | 0.010 |
Why?
|
| Cholesterol | 1 | 2004 | 64 | 0.010 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 1995 | 37 | 0.010 |
Why?
|
| Ultrasonography, Doppler | 1 | 2004 | 16 | 0.010 |
Why?
|
| ROC Curve | 1 | 2004 | 145 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 201 | 0.010 |
Why?
|
| Young Adult | 1 | 2011 | 2104 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2005 | 110 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 108 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 352 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 364 | 0.010 |
Why?
|
| Aging | 1 | 1993 | 1578 | 0.010 |
Why?
|
| Observer Variation | 1 | 2003 | 104 | 0.010 |
Why?
|
| Heart Rate | 2 | 1989 | 117 | 0.010 |
Why?
|
| Child | 1 | 1986 | 1424 | 0.010 |
Why?
|
| Acute Disease | 1 | 2002 | 208 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2002 | 162 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2005 | 3615 | 0.010 |
Why?
|
| Hospitalization | 1 | 2002 | 323 | 0.010 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 1999 | 8 | 0.010 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 1999 | 5 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2001 | 599 | 0.010 |
Why?
|
| Syndrome | 1 | 1999 | 82 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 1999 | 49 | 0.010 |
Why?
|
| Stents | 1 | 1999 | 86 | 0.010 |
Why?
|
| Acebutolol | 1 | 1997 | 1 | 0.010 |
Why?
|
| Chlorthalidone | 1 | 1997 | 1 | 0.010 |
Why?
|
| Amlodipine | 1 | 1997 | 4 | 0.010 |
Why?
|
| Doxazosin | 1 | 1997 | 2 | 0.010 |
Why?
|
| Enalapril | 1 | 1997 | 4 | 0.010 |
Why?
|
| Libido | 1 | 1997 | 6 | 0.010 |
Why?
|
| Orgasm | 1 | 1997 | 11 | 0.010 |
Why?
|
| Penile Erection | 1 | 1997 | 27 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1995 | 267 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 1994 | 97 | 0.010 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 1993 | 11 | 0.010 |
Why?
|
| Catecholamines | 1 | 1993 | 9 | 0.010 |
Why?
|
| Drug Monitoring | 1 | 1993 | 18 | 0.010 |
Why?
|
| Bias | 1 | 1993 | 41 | 0.010 |
Why?
|
| Eating | 1 | 1993 | 59 | 0.010 |
Why?
|
| Minnesota | 1 | 1992 | 9 | 0.010 |
Why?
|
| Models, Cardiovascular | 1 | 1992 | 15 | 0.010 |
Why?
|
| Software | 1 | 1992 | 68 | 0.010 |
Why?
|
| Catheterization, Peripheral | 1 | 1992 | 19 | 0.010 |
Why?
|
| Equipment Design | 1 | 1992 | 155 | 0.010 |
Why?
|
| Linear Models | 1 | 1992 | 255 | 0.010 |
Why?
|
| Labetalol | 1 | 1989 | 6 | 0.010 |
Why?
|
| Supination | 1 | 1989 | 20 | 0.010 |
Why?
|
| Time Factors | 1 | 1993 | 1498 | 0.010 |
Why?
|
| Thermodilution | 1 | 1989 | 6 | 0.010 |
Why?
|
| Random Allocation | 1 | 1989 | 130 | 0.000 |
Why?
|
| Acute Kidney Injury | 1 | 1989 | 47 | 0.000 |
Why?
|
| Respiratory Insufficiency | 1 | 1989 | 52 | 0.000 |
Why?
|
| Angiography | 1 | 1988 | 34 | 0.000 |
Why?
|
| Cost-Benefit Analysis | 1 | 1987 | 134 | 0.000 |
Why?
|
| Angina Pectoris | 2 | 1976 | 18 | 0.000 |
Why?
|
| Methods | 1 | 1976 | 13 | 0.000 |
Why?
|
| Angiocardiography | 1 | 1975 | 1 | 0.000 |
Why?
|
| Phonocardiography | 1 | 1975 | 1 | 0.000 |
Why?
|